Current Assets
Cash, Cash Equivalents, and Marketable Securities
Vertex Pharmaceuticals Cash, Cash Equivalents, and Marketable Securities decreased by 43.2% to $463.10M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.3%, from $443.80M to $463.10M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalHigher is better
VolatilityVolatile
First reportedQ3 2018
Last reportedQ4 2025
How to read this metric
Higher levels indicate strong liquidity and financial health, while lower levels may signal a need for external financing.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term invest...
Peer comparison
A standard liquidity metric reported by virtually all public companies on the balance sheet.
Metric ID:
cash_equivalents_marketable_securities_totalHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.17B | $4.08B | $3.98B | $4.88B | $5.68B | $4.11B | $702.70M | $2.13B | $2.28B | $4.00B | $4.60B | $443.80M | $1.10B | $816.00M | $463.10M |
| QoQ Change | — | -2.2% | -2.5% | +22.6% | +16.6% | -27.8% | -82.9% | +203.1% | +7.0% | +75.4% | +15.0% | -90.4% | +147.9% | -25.8% | -43.2% |
| YoY Change | — | — | — | — | +36.4% | +0.7% | -85.6% | -62.5% | -44.5% | +469.2% | +116.0% | -80.5% | -72.5% | -82.3% | +4.3% |
Range$443.80M – $5.68B
CAGR-46.6%
Avg YoY Growth+18.1%
Median YoY Growth-44.5%
Current Streak2 quarters decline
Cash, Cash Equivalents, and Marketable Securities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's cash, cash equivalents, and marketable securities?
- Vertex Pharmaceuticals (VRTX) reported cash, cash equivalents, and marketable securities of $463.10M in Q3 2025.
- How has Vertex Pharmaceuticals's cash, cash equivalents, and marketable securities changed year-over-year?
- Vertex Pharmaceuticals's cash, cash equivalents, and marketable securities increased by 4.3% year-over-year, from $443.80M to $463.10M.
- What does cash, cash equivalents, and marketable securities mean?
- The total value of the company's cash and highly liquid short-term investments.